4,4'-(oxybis(methylene))dianiline | 96727-43-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-(oxybis(methylene))dianiline
• 英文别名: di(4-aminobenzyl) ether；4,4'-(2-oxa-propanediyl)-di-aniline；4,4'-(2-Oxa-propandiyl)-di-anilin；Bis-(4-amino-benzyl)-aether；4-[(4-aminophenyl)methoxymethyl]aniline
• CAS: 96727-43-4
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.294
• InChiKey: PRLDILURXJMICQ-UHFFFAOYSA-N

物化性质

• 沸点：
  410.0±30.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,4'-(oxybis(methylene))dianiline 在 sodium hydroxide 、 盐酸 作用下， 以 乙醇 、 乙腈 为溶剂， 以73%的产率得到N,N'-((oxybis(methylene))bis(4,1-phenylene))dipicolinimidamide hydrochloride
  参考文献：
  名称：

  Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides

  摘要：

  The effects of reducing the molecular weight of the antileishmanial compound DB766 on DNA binding affinity, antileishmanial activity and cytotoxicity are reported. The bis-arylimidamides were prepared by the coupling of aryl S-(2-naphthylmethyl)thioimidates with the corresponding amines. Specifically, we have prepared new series of bis-arylimidamides which include 3a, 3b, 6, 9a, 9b, 9c, 13, and 18. Three compounds 9a, 9c, and 18 bind to DNA with similar or moderately lower affinity to that of DB766, the rest of these compounds either show quite weak binding or no binding at all to DNA. Compounds 9a, 9c, and 13 were the most active against Leishmania amazonensis showing IC50 values of less than 1 mu M, so they were screened against intracellular Leishmania donovani showing outstanding activity with IC50 values of 25-79 nM. Despite exhibiting little in vitro cytotoxicity these three compounds were quite toxic to mice. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.058
• 作为产物：
  描述：

  1,1'-[氧基二(亚甲基)]二(4-硝基苯) 在 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 2.5h， 以98%的产率得到4,4'-(oxybis(methylene))dianiline
  参考文献：
  名称：

  Chemoselective hydrogenation of nitrobenzyl ethers to aminobenzyl ethers catalyzed by palladium–nickel bimetallic nanoparticles

  摘要：

  A highly efficient and chemoselective hydrogenation of nitrobenzyl ethers to aminobenzyl ethers was developed by using a novel palladium nickel bimetallic nanocatalyst. Since the catalytic selectivity was resulted from the synergistic effects between two metals rather than the traditional catalyst poisons, the hydrogenation proceeded smoothly under additive-free conditions. Thus, the work-up procedure was as simple as to recover the catalyst by a magnetic separation and then to evaporate the solvent. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.10.037

文献信息

• [EN] ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF<br/>[FR] LIEURS D'ACYLHYDRAZONE, PROCÉDÉS ET UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019109188A1

  公开（公告）日：2019-06-13

  The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.

  目前的应用涉及公式(I)-(VI)的化合物：(I)、(II)、(III)、(IV)、(V)、(VI)、(VII)和(VIII)，包含这些化合物的组合物及其用途，例如作为药物和/或诊断剂。
• CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
  申请人：Sufi Bilal

  公开号：US20100145036A1

  公开（公告）日：2010-06-10

  The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物和药物可切割底物共轭物，它们是有效的细胞毒素。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• [EN] UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF<br/>[FR] LIEURS À BASE D'HÉTÉROCYCLOALKYLE ET D'ACYLHYDRAZONE HÉTÉROAROMATIQUE INSATURÉS, PROCÉDÉS ET UTILISATIONS ASSOCIÉS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2020248065A1

  公开（公告）日：2020-12-17

  The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemical entities together for further use as medicaments and/or diagnostics.

  本申请涉及Formula (I)、(II)、(III)或(IV)化合物，包括这些化合物的组合物、其制备方法以及它们的用途，例如作为酰基腙偶联剂，可以将两种化学实体连接在一起，以进一步用作药物和/或诊断。
• [EN] ASYMMETRIC CONJUGATE COMPOUNDS<br/>[FR] COMPOSÉS CONJUGUÉS ASYMÉTRIQUES
  申请人：FEMTOGENIX LTD

  公开号：WO2017194960A1

  公开（公告）日：2017-11-16

  The invention relates to compound of formula (I): A-X1-L-X2-B and salts, solvates and tautomers thereof, which are useful as medicaments, in particular as anti-proliferative agents and for use as a drug in an antibody-drug conjugate; wherein A is a group selected from (A1), (A2), (A3), (A4) and (A5); X1 and X2 are independently selected from O, S, NR28, CR28R29, CR28R29O, C(=O), C(=O)NR28, NR28C(=O), C(O)-RA-C(O)-NH, C(O)-RA-NH-C(O), C(O) -NH-RA-C(O), NH-C(O)-RA-C(O), NH-C(O)-RA-C(O)-NH, NH-C(O)-RA-NH-C(O), C(O)-NH-RA-NH-C(O), C(O)-NH-RA-C(O)-NH, O-C(O) and C(O)-O or is absent; L is selected from an amino acid, a peptide chain having from 2 to 12 amino acids, a paraformaldehyde chain –(OCH2)1-24-, a polyethylene glycol chain -(OCH2CH2)1-12- and –(CH2)m-Y6-(CH2)n- wherein Y6 is selected from –(CH2)z- and a group (L1) a group (L1) that is selected from arylene, monocyclic heteroarylene, monocyclic cycloalkylene, monocyclic cycloalkenylene and monocyclic heterocyclylene groups optionally substituted with up to three optional substituent groups; and B is a polycyclic group selected from (B1), (B2) and (B3).

  该发明涉及化合物的公式(I)：A-X1-L-X2-B及其盐、溶剂合物和互变异构体，其作为药物具有实用性，特别是作为抗增殖剂并用作抗体药物结合物中的药物；其中A是从(A1)、(A2)、(A3)、(A4)和(A5)中选择的基团；X1和X2分别选择自O、S、NR28、CR28R29、CR28R29O、C(=O)、C(=O)NR28、NR28C(=O)、C(O)-RA-C(O)-NH、C(O)-RA-NH-C(O)、C(O)-NH-RA-C(O)、NH-C(O)-RA-C(O)、NH-C(O)-RA-C(O)-NH、NH-C(O)-RA-NH-C(O)、C(O)-NH-RA-NH-C(O)、C(O)-NH-RA-C(O)-NH、O-C(O)和C(O)-O或者不存在；L选择自氨基酸、具有2至12个氨基酸的肽链、对甲醛链-(OCH2)1-24-、聚乙二醇链-(OCH2CH2)1-12-和-(CH2)m-Y6-(CH2)n-，其中Y6选择自-(CH2)z-和一个基团(L1)，该基团(L1)选择自芳基、单环杂芳基、单环环烷基、单环环烯烃基和单环杂环烷基，可选地取代高达三个可选取代基团；B是从(B1)、(B2)和(B3)中选择的多环基团。
• [EN] ANTIBODY DRUG CONJUGATES WITH CLEAVABLE LINKERS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT POURVUS DE LIEURS CLIVABLES
  申请人：HEIDELBERG PHARMA RES GMBH

  公开号：WO2020234461A1

  公开（公告）日：2020-11-26

  The present invention relates to prodrugs comprising a linker comprising five- or six-membered cyclic acetals and an adjacent specific cleavage site, and to precursor compounds for the synthesis of said prodrugs. In one aspect the present invention relates to antibody-targeted amatoxin conjugates comprising said linkers, to methods for their synthesis, and to the use of said antibody-targeted amatoxin conjugates. In a further aspect, the invention relates to pharmaceutical compositions comprising said conjugates, and to the use of said conjugates or compositions for therapeutic purposes, in particular for tumor therapy and oncology.

  本发明涉及包含具有五元或六元环缩醛的连接物以及相邻特定裂解位点的前药，以及用于合成所述前药的前体化合物。在一个方面，本发明涉及包含所述连接物的抗体靶向阿毛氧素结合物，以及其合成方法和所述抗体靶向阿毛氧素结合物的应用。在另一个方面，该发明涉及包含所述结合物的药物组合物，以及用于治疗目的，特别是用于肿瘤治疗和肿瘤学的所述结合物或组合物的应用。